ELAN PHARMA INTERNATIONAL LIMITED. Patent applications |
Patent application number | Title | Published |
20120100209 | CONTROLLED RELEASE COMPOSITIONS COMPRISING A COMBINATION OF ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE - The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile. | 04-26-2012 |
20120083003 | PARKIN SUBSTRATE AND ASSAY - The invention provides in vitro, ex vivo, and in vivo assays for Parkin activity, in which Parkin-mediated ubiquitination of a Sept4 protein is measured. The assays may be used to screen for agents that modulate Parkin protein ligase activity. | 04-05-2012 |
20120003319 | COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB AND METHODS OF USE - The invention provides an oral formulation for administering to a subject comprising an imatinib compound and an enteric matrix or enteric coating or a combination thereof, whereby at least 80% of the imatinib compound is released in the small intestine of the subject. Methods of using such formulation is also provided. | 01-05-2012 |
20110275999 | DRUG DELIVERY DEVICE - A drug delivery device having a housing containing a gas generator controlled by an electronic controller. The gas generator generates gas into a reciprocable chamber, whereby reciprocation of the chamber causes a lever to reciprocate a pawl, and this action causes a ratchet to The device may also be provided with manually control for delivering a bolus dose Of drug when necessary. | 11-10-2011 |
20110270218 | DRUG DELIVERY DEVICE - A drug delivery device having a housing containing a gas generator controlled by an electronic controller. The gas generator generates gas into a reciprocable chamber, whereby reciprocation of the chamber causes a lever to reciprocate a pawl, and this action causes a ratchet to The device may also be provided with manually control for delivering a bolus dose of drug when necessary. | 11-03-2011 |
20110223244 | ALCOHOL RESISTANT ENTERIC PHARMACEUTICAL COMPOSITIONS - Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof. | 09-15-2011 |
20110177066 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES - Passive immunotherapy methods for treating a patient having AL amyloidosis characterized by the presence of amyloid light chain-type protein fibrils. | 07-21-2011 |
20110064803 | NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2 - The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of osteoporosis. The invention also relates to a controlled release composition comprising a vitamin K2 or a nanoparticulate vitamin K2 that in operation delivers the drug in a pulsed or multi-modal manner for the prevention and treatment of osteoporosis. | 03-17-2011 |
20100260859 | CONTROLLED-RELEASE CLOZAPINE COMPOSITIONS - A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of clozapine having an effective average particle size of less than or about 2 μm and at least one surface stabilizer adsorbed on the surface of the clozapine particles, and a solubilizing agent. | 10-14-2010 |
20100260858 | DRUG DELIVERY COMPOSITION - A composition for delivery of a drug is disclosed. The composition has a semipermeable coating, particles of a medicament having an effective average particle size of less than or about 2 μm and at least one surface stabilizer adsorbed on the surface of the medicament particles, and a solubilizing agent. | 10-14-2010 |
20100143946 | ALPHA-SYNUCLEIN KINASE - The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase. | 06-10-2010 |
20090297596 | Nanoparticulate and Controlled Release Compositions Comprising a Platelet Aggregation Inhibitor - The present invention provides a composition comprising a platelet aggregation inhibitor, for example, cilostazol, or a salt or derivative thereof, useful in the treatment and prevention of ischemic symptoms. The invention provides a composition which comprises nanoparticulate particles comprising the platelet aggregation inhibitor and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. The invention provides also a composition that delivers a platelet aggregation inhibitor, or nanoparticles comprising the same, in a pulsatile or continuous manner. | 12-03-2009 |
20090269400 | Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin - The present invention is directed to compositions comprising a nanoparticulate antibiotic having improved bioavailability. Preferably, the antibiotic comprises nanoparticulate cephalosporin particles with an effective average particle size of less than about 2000 nm and are useful in the treatment of bacterial infection. The invention also relates to a controlled release composition comprising a cephalosporin or a nanoparticulate cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The nanoparticulate cephalosporin particles may be formulated as a controlled release drug delivery system whereby the particles are coated one or more times with one or more natural or synthetic hydrophilic or hydrophobic polymer coating materials or dispersed throughout a natural or synthetic hydrophilic and/or hydrophobic polymer matrix. | 10-29-2009 |
20090252807 | Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives - The present invention is directed to compositions comprising a nanoparticulate prostaglandin derivative, preferably limaprost or a salt or derivative thereof, having improved bioavailability. The nanoparticulate prostaglandin derivative particles of the composition have an effective average particles size of less than about 2000 nm and are useful in the treatment of ischemic symptoms. The invention also relates to a controlled release composition comprising a prostaglandin derivative, such as limaprost alfadex, or a nanoparticulate prostaglandin derivative, such as limaprost or a salt or derivative thereof, that in operation delivers the drug in a pulsed or bimodal manner for the treatment of ischemic symptoms. | 10-08-2009 |
20090238884 | COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB AND METHODS OF USE - The invention provides an oral formulation for administering to a subject comprising an imatinib compound and an enteric matrix or enteric coating or a combination thereof, whereby at least 80% of the imatinib compound is released in the small intestine of the subject. Methods of using such formulation is also provided. | 09-24-2009 |
20090191231 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same. | 07-30-2009 |
20090155331 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS - Described are injectable formulations of particulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise particulate olanzapine. | 06-18-2009 |
20090155256 | Immunotherapy Regimes Dependent On APOE Status - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient. | 06-18-2009 |
20090149479 | DOSING REGIMEN - Methods and kits are provided enabling a twice daily dosing regimen that achieves daily patient blood levels of active pharmaceutical ingredient comparable to a dosing regimen requiring the same active ingredient to be administered three times a day. | 06-11-2009 |
20090142270 | PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY - The invention provides improved agents and methods for treatment of cerebral amyloid angiopathy (CAA) and methods to effect prophylaxis of CAA. The methods can treat CAA concurrently with Alzheimer's disease or separately. The methods can effect prophylaxis of CAA concurrently with Alzheimer's disease or separately. The methods involve administering antibody that is specific for the N-terminus of Aβ or an agent that can induce such an antibody. | 06-04-2009 |
20080268043 | Controlled Release Compositions Comprising an Antipsychotic Agent - The invention relates to a formulation for the treatment of acute manic episodes associated with Bipolar I Disorder comprising an antipsychotic agent selected from the group consisting of: a dibenzothiazepine derivative; lithium; and divalproex. The formulation comprises a first component which comprises a first population the antipsychotic agent and at least one subsequent component which comprises a subsequent population of the antipsychotic agent and which allows for the modified release of the agent. The combination of the first and the subsequent components in operation deliver the antipsychotic agent in a pulsed or controlled manner over a period of up to twenty-four hours. | 10-30-2008 |
20080227719 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same. | 09-18-2008 |
20080227718 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE - The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same. | 09-18-2008 |